We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Track real-time Director Deals activity on the London Stock Exchange (LSE)
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.15 | 4.17% | 3.75 | 229,705 | 11:26:32 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 3.50 | 4.00 | 3.75 | 3.60 | 3.60 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 4.3M | -1.91M | -0.0036 | -10.42 | 19.2M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:18:51 | O | 66,967 | 3.566 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/6/2025 | 13:40 | UK RNS | Eden Research plc Result of AGM |
| 18/6/2025 | 07:00 | UK RNS | Eden Research plc AGM Statement |
| 16/6/2025 | 16:45 | ALNC |  Eden Research partners with Royal Holloway on seed treatment product |
| 16/6/2025 | 07:00 | UK RNS | Eden Research plc Ecovelex Partnership with Royal Holloway |
| 27/5/2025 | 17:22 | UK RNS | Eden Research plc Notice of AGM |
| 13/5/2025 | 13:20 | ALNC | TRADING UPDATES: Eden Research in California backing; Zinc Media award |
| 13/5/2025 | 11:02 | ALNC | AIM WINNERS & LOSERS: Revolution Beauty eyes fundraise as profit down |
| 13/5/2025 | 07:00 | UK RNS | Eden Research plc Mevalone Approval in California - Powdery Mildew |
| 09/5/2025 | 07:00 | UK RNS | Eden Research plc Investor Presentation via Investor Meet Company |
| 06/5/2025 | 12:47 | ALNC | EARNINGS AND TRADING: Facilities by ADF swings to loss; ITM wins deal |
Eden Research (EDEN) Share Charts1 Year Eden Research Chart |
|
1 Month Eden Research Chart |
Intraday Eden Research Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 18/6/2025 | 18:33 | Eden Research | 21,221 |
| 13/3/2025 | 09:37 | Eden Research - Who Is Behind Thallo Eco Products Corp? | 28 |
| 20/1/2025 | 17:23 | Eden....Onward and Upwards! | 53 |
| 21/6/2023 | 12:05 | The sterile garden of Eden | 123 |
| 29/3/2022 | 16:04 | Eden Research | 14 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 22/6/2025 09:20 by Eden Research Daily Update Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 3.60p.Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £20,000,720. Eden Research has a price to earnings ratio (PE ratio) of -10.42. This morning EDEN shares opened at 3.60p |
Posted at 13/6/2025 08:42 by investingisatrickygame Super,if you are correct, Corteva could acquire a position in Eden by going to market. I think it is called a Tender Offer. In doing so they could seek to acquire, say, 20% of the Company and offer ALL shareholders X pence. So they would have a stake in Eden and no doubt a stronger working relationship. Now, that wouldn't be a cash injection into Eden, but Eden has said it doesn't need cash. Therefore, it must know what revenues will come into the Company this year with some certainty or perhaps there is a transactional event elsewhere, logically around the insecticide wouldn't you think? In any event, Eden appears confident and whether or not Corteva wants a piece of Eden, we will have to wait and see. |
Posted at 19/5/2025 09:27 by alchemy Well last week was a good week I'm talking my book here by the way Now let's move onto The Spectre of Profitability For the first time to my knowledge the FD acknowledged profitability might be possible for FY 2026. But we're not yet halfway through 2025 so that set me thinking about what the benefit to EDENs share price talk of and signals pointing to profitability might be . And if of benefit when we may see it.As always regulatory news will play a key part. That applies to regulation affecting both products and territories and label extensions .And new developments for example insecticide.These were covered in the presentation as possible upsides to 2025 and 2026 but clearly also to the years ahead. (Personally I like the idea we could reach £100 million turnover by the end of the decade).If we had two upside announcements of enhancing revenue fourfold then we'd have an eightfold uptick from where we are . Don't forget one of those fourfold had previously been proposed as a ten timeser - Super is chasing that. Conservatively we take one uptick of four a current turnover of four and get a revenue of 16. A margin of forty per cent gives 7.2 and with overheads of 5.2 that gives a maiden profit of 2 . That at a P/E of 50 gives a Marcap of 100 mill plus which apparently allows some big boys to invest. Share price a little over 19p at a P/E of a plausible 50)The key question is when would the prospect of moving into profit be acted upon , and discounted on the share price? What do you think ? To start the thoughts going So by end July a fourfolder pops up. That helps cash this year but as above sets next year's turnover gets to 16 million pounds see above . I know what I think . Higher nearly five times higher When ? Well, well before Dec 31st this year . |
Posted at 15/5/2025 13:06 by investingisatrickygame When you look at the forecast revenue slide, repeated from 13/2/2025, we know that Eden has forecast £5 million turnover for 2025 which could be materially affected by the positive timing of 3 RNS's, arguably 2 of which are overdue.When you take account of Esseva values and Ecovelex values (up to €12 million) and you further add Mevalone and Cedroz anticipated increased sales, you can see that Eden is potentially looking at £15-£20 million turnover next year. That would be my take on that slide. Alex Abrey said that the EU and US values of €39 million euros from the same slide is for the near term and then qualified that as the next 2 years, so I think £15-£20 million in 2026 is not an unreasonable assessment. Sean Smith also said that they anticipate making a profit in 2026 which AA qualified yesterday saying that was doable if these RNS's fall in time. So the trajectory looks like £5 million to circa £35 million in two years which will be more than enough working capital to not necessitate any capital raises, will put the Company in profit and in my opinion will make them look attractive to other parties with the visibility of €135 million on the horizon for a company that has both the financial resources and people resources to expedite global regulatory submissions on existing products. Then add in the strong pipeline of new products that SS referred to yesterday and both the immediate and long-term prospects of value for shareholders and any company that may come knocking, lok very, very good. Perhaps that is why SS said they are so disappointed with the share price and that today's price represents a great opportunity |
Posted at 13/5/2025 09:29 by neutralpov Investingisatrickyga13 May '25 - 07:36 - 20980 of 20981 > .... the share price which should be north of 20p and some. > Time will tell. ROTFLMAO!!! Time will tell whether you get ten years in jail, you stinking paid ramping CR00K, or twenty years, the maximum possible even though you are such a prolific cheater. As to the SP, the current miniblip is to SUCK IN some more effin' mugs. The BORED OF DIFECTORS *STILL* AREN'T BUYING, plonker. Soon share price back down to BELOW 2p. Cast in iron. lol |
Posted at 13/5/2025 07:36 by investingisatrickygame Morning Super,Well, we are told that Corteva in France with Esseva (Mevalone re-branded under their distributor deal) will do 10* previous sales when it is approved for Powdery Mildew. California has an addressable market of €94 million, Sipcam are a perfect partner and are chomping on the bit to get going in the US. Effectively, California is the market. It is clear that California alone on just Mevalone could and likely will double Eden's current turnover of £4.4 Million. Eden needs 5% of that market. Did Eden launch in the US to get less that a 5% market share? I doubt it very much. MNS, that label extension is extremely helpful and valuable for Eden. Much as you may mock, perhaps through understandable investment disappointment in Eden thus far, this is in my opinion, a material label extension that shareholders should be excited about. I'm pretty sure both Eden and Sipcam are and I choose to believe they haven't increased revenue targets this year based on this approval as they are being extremely cautious, likely unnecessarily so given it is available for the 2025 season. We now await the three key RNS's, all due and I personally expect those three RNS's to appropriate fair value in the share price which should be north of 20p and some. Time will tell. |
Posted at 06/5/2025 11:20 by jaknife supersonico,"What the a mistake Ken makes by discounting the fact that Eden are working with Syngenta..?" Your mistakes you donkey! You've been obsessed with this share for over a decade. You've p'd away more than ten years of your life thinking night and day about just one company that is a complete and utter crock of 💩. The share price has recently bounced off of its all time low and so pretty much every Eden investor is sitting on thumping losses - especially those investors that have doggedly followed the pup for over a decade! You are the perfect example of what NOT to be like when you invest in shares. You have the most obviously wrong psychology - always looking for the slightest positive in every statement even when that statement is disastrously bad. You are the "Black Knight" of investing: Monty Python - The Black Knight - Tis But A Scratch And I have no doubt that, when Eden ultimately goes bust and you lose all your money, you will find some reason why it's not your fault and hence why someone else should be blamed. In the meantime, you are the perfect example to everyone out there in the world of how NOT to invest, how to doggedly stick to your beliefs regardless of the factual evidence that presents itself to you and how to seek out confirmation bias in every piece of "research" that you delusionally call the time that you spend dreaming about Eden. Keep up the good work and thank you from the "other side". JakNife |
Posted at 26/4/2025 10:19 by investingisatrickygame Morning Super,Let's add to post 20854 shall we In the recent Times newspaper article and the post on Linkedin for the same we had the following comments " As one of the leading independent biopesticide companies developing natural crop protection solutions, Eden is leading the charge to replace conventional chemistry in the face of increasing regulatory and consumer pressure. QUESTION: In what way is Eden 'one of the leading'? Can that be explained and quantified? If so, it would be helpful to better understand this QUESION: Can Eden please explain how it is 'leading the charge' and what does this look like? From the article 'We should really clean up there' in regards to Europe and Mevalone @There is huge growth opportunity' Also that Eden will be profitable in 2026 Two years ago the Chairman at the AGM closed by saying 'you will look back in 2 years and realise what a game-changer Ecovelex is' There is so much to explore and explain to propel the share price. I could make a much longer list from Eden's statements |
Posted at 02/4/2025 16:53 by kenmitch supersonicoI haven’t a clue what your Greenlight hypotheses is. Whatever it is what matters to sensible and competent investors is how the share price of their holdings performs. And a 99% Eden share price fall shows that whatever your theory is it has done nothing for the share price. |
Posted at 02/4/2025 16:05 by kenmitch supersonico.Two key points in response to your questions. 5 up ticks for your post shows there are still a few as disillusioned as you are about EDEN. And the share price down 99% shows clearly what’s wrong with your hypothesis. Here’s a link for this thread (post 4000) in June 2018, so nearly 6 years ago. What does it show? Just like now; post after post on Eden from supersonico. You’ve spent so many years here wasting your time imo posting over and over again almost every day, while the share price, apart from occasional bounces, has fallen relentlessly. Surely you and the few others posting regularly here can see the simple investment case for EDEN? It’s don’t buy until clear evidence of increased sales. IF that ever happens, which looks unlikely, EDEN could at last see a sustained rising share price, if those increased sales are then followed by more still. Until that day EDEN is dead money at best, and at worst if they can’t get support for yet another fund raise, EDEN is going to go bust. |
Posted at 01/4/2025 09:20 by neutralpov This summary is generated automatically by ADVFN and is based on analysis of the share price chart, RNSs, chat contents and who knows what else:"Discussion Insights Investor discussions for Eden Research Plc (EDEN) have taken a notably pessimistic turn, with the share price declining dramatically—d Despite the dismal share performance, there remains a faction within the community, such as user supersonico, who continues to advocate investment in Eden, stating, "From small steps, big things can grow!" Additionally, some discussions hint at potential future partnerships and ongoing non-disclosure agreements (NDAs), with claims of new NDA signings monthly. However, these assertions have been met with skepticism, as reflected in neutralpov's critical remarks on the reliability of insiders and what they perceive as rampant speculation. The overwhelming sentiment is encapsulated by bjlk, who lamented, “it has never delivered on share price, sales—it's all just round the corner,” signaling a collective frustration around performance and managerial accountability. Investors are left weighing whether to hold on amidst the turbulence or cut their losses." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
